Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
RUNX3 CRISPR/Cas9 KO Plasmid (m): sc-419487
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- RUNX3 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the RUNX3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: RUNX3 Antibody (A-3): sc-376591
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
RUNX3 CRISPR/Cas9 KO Plasmid (m) | sc-419487 | 20 µg | $397.00 |
Overview
Runx3 encodes the transcription factor RUNX3, a Runt-domain DNA-binding protein that partners with CBFB to regulate lineage specification and differentiation programs in multiple tissues. In mouse immune and epithelial systems, RUNX3 integrates signals from pathways such as TGF-β/SMAD and developmental transcriptional networks to control cell fate decisions, maturation, and context-dependent growth regulation. Altered Runx3 activity has been linked to dysregulated transcriptional programs relevant to inflammation, tumorigenesis, and neurodevelopmental phenotypes in model organisms. As a node in promoter and enhancer regulation, RUNX3 is frequently studied for its impact on chromatin-dependent gene expression and downstream pathway remodeling.
RUNX3 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Runx3 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Runx3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Runx3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish RUNX3 protein expression.
This CRISPR knockout system enables efficient generation of Runx3-deficient cell models for investigation of RUNX3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Runx3 exon(s) critical for RUNX3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Runx3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by RUNX3 CRISPR/Cas9 KO Plasmid (m) and RUNX3 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Runx3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by RUNX3 HDR Plasmid (m) and RUNX3 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Runx3 homology arms to support homology-directed repair at defined Runx3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.